Literature DB >> 17436576

Review. Clinical pharmacokinetics of bortezomib.

Dominique Levêque1, Marie Christine Monteiro Carvalho, Frederic Maloisel.   

Abstract

This review presents the clinical pharmacokinetics of bortezomib. Aspects regarding metabolism, pharmacodynamics and drug interactions are also discussed.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17436576

Source DB:  PubMed          Journal:  In Vivo        ISSN： 0258-851X            Impact factor:   2.155


  19 in total

Review 1.  Next-generation proteasome inhibitors for cancer therapy.

Authors:  Ji Eun Park; Zachary Miller; Yearin Jun; Wooin Lee; Kyung Bo Kim
Journal:  Transl Res       Date:  2018-03-26       Impact factor: 7.012

Review 2.  Bortezomib for the treatment of mantle cell lymphoma: an update.

Authors:  Bryan Hambley; Paolo F Caimi; Basem M William
Journal:  Ther Adv Hematol       Date:  2016-05-21

3.  Proteasome inhibition increases recruitment of IκB kinase β (IKKβ), S536P-p65, and transcription factor EGR1 to interleukin-8 (IL-8) promoter, resulting in increased IL-8 production in ovarian cancer cells.

Authors:  Bipradeb Singha; Himavanth Reddy Gatla; Subrata Manna; Tzu-Pei Chang; Shannon Sanacora; Vladimir Poltoratsky; Ales Vancura; Ivana Vancurova
Journal:  J Biol Chem       Date:  2013-12-11       Impact factor: 5.157

4.  Physiologically-based pharmacokinetic modeling of target-mediated drug disposition of bortezomib in mice.

Authors:  Li Zhang; Donald E Mager
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-09-21       Impact factor: 2.745

5.  Novel phase I study combining G1 phase, S phase, and G2/M phase cell cycle inhibitors in patients with advanced malignancies.

Authors:  Rajul K Jain; David S Hong; Aung Naing; Jennifer Wheler; Thorunn Helgason; Nai-Yi Shi; Yash Gad; Razelle Kurzrock
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

6.  The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges.

Authors:  G R Tundo; D Sbardella; A M Santoro; A Coletta; F Oddone; G Grasso; D Milardi; P M Lacal; S Marini; R Purrello; G Graziani; M Coletta
Journal:  Pharmacol Ther       Date:  2020-05-19       Impact factor: 12.310

7.  Safety and comfort of domestic bortezomib injection in real-life experience.

Authors:  Claudio Cerchione; Davide Nappi; Anna Emanuele Pareto; Maria Di Perna; Irene Zacheo; Marco Picardi; Fabrizio Pane; Lucio Catalano
Journal:  Support Care Cancer       Date:  2018-03-24       Impact factor: 3.603

8.  Anticancer drug bortezomib increases interleukin-8 expression in human monocytes.

Authors:  Shannon Sanacora; Joaquin Urdinez; Tzu-Pei Chang; Ivana Vancurova
Journal:  Biochem Biophys Res Commun       Date:  2015-03-16       Impact factor: 3.575

9.  Cancerous inhibitor of protein phosphatase 2A determines bortezomib-induced apoptosis in leukemia cells.

Authors:  Chun-Yu Liu; Chung-Wai Shiau; Hsin-Yu Kuo; Hsiang-Po Huang; Ming-Huang Chen; Cheng-Hwai Tzeng; Kuen-Feng Chen
Journal:  Haematologica       Date:  2012-09-14       Impact factor: 9.941

10.  Proteasome inhibition by bortezomib increases IL-8 expression in androgen-independent prostate cancer cells: the role of IKKα.

Authors:  Subrata Manna; Bipradeb Singha; Sai Aung Phyo; Himavanth Reddy Gatla; Tzu-Pei Chang; Shannon Sanacora; Sitharam Ramaswami; Ivana Vancurova
Journal:  J Immunol       Date:  2013-07-26       Impact factor: 5.422
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.